---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019083"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:23:50.453499+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IDEAYA Q1 2023: $351.2M cash, darovasertib 45% ORR in 1L MUM, starting Phase 2/3

## Summary
- Cash, equivalents & marketable securities $351.2M as of Mar 31, plus $188.7M net from Apr offering, funding into 2027.
- Darovasertib + crizotinib Phase 2: 45% ORR, 90% DCR, ~7 mo median PFS in 1L MUM; 30% ORR any-line MUM.
- Initiating Phase 2/3 registrational trial in 1L HLA-A2(-) MUM in Q2 2023 with median PFS primary endpoint.
- Neoadjuvant darovasertib case: ~80% ocular tumor shrinkage, avoided enucleation, restored 6/5 vision.
- IDE161 first cohort enrolled in Phase 1; Pol Theta Helicase IND targeted Q2 2023 ($7M GSK milestone).

## SEC filing metadata
- accession: 0000950170-23-019083
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017023019083/0000950170-23-019083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017023019083/idya-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019083
- JSON: https://secwatch.observer/filing/0000950170-23-019083.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019083.txt

## Key facts
- Earnings Releases
  IDEAYA Biosciences, Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 9, 2023, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000095017023019083/0000950170-23-019083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.